NCT00640523

Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 23 (actual)
• Sponsor: BioCryst Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the effectiveness and safety of forodesine in CLL patients

Detailed description

To investigate the efficacy (complete response \[CR\] + partial response \[PR\]) of forodesine in treating subjects with CLL who have failed at least one prior treatment regimen or who are treatment naïve but are either elderly, have poor performance status or are otherwise predicted not to tolerate cytotoxic chemotherapy.

Conditions

• Chronic Lymphocytic Leukemia (CLL)

Interventions

Type	Name	Description
DRUG	forodesine HCl	2 x 100mg capsules daily

Timeline

• Start date: 2008-03-01
• Primary completion: 2010-11-01
• Completion: 2011-11-01
• First posted: 2008-03-21
• Last updated: 2012-01-23

Locations

11 sites across 2 countries: United States, Australia